More Than Pathogen Reduction: Seraph 100 In COVID-19 Patients
ExThera Medical was formed in 2007 through a joint venture between the Emergence Venture Partners Life Science Incubator and ExThera AB, at the Karolinska Institute of Stockholm. We are focused on therapeutic applications to treat drug-resistant and drug-susceptible bloodstream infections in high-risk patient populations, with field deployable versions for biodefense and military.
The company’s first product, the Seraph® 100 Microbind® Affinity Blood Filter, is CE Marked for the reduction of pathogens during bloodstream infections in adjunction to antibiotics and commercially available in Europe.
Registration available online here
Tue, 1 Dec 2020 - Fri, 4 Dec 2020
Wed, 2 Dec 2020 - Fri, 4 Dec 2020
Fri, 4 Dec 2020 - Sat, 12 Dec 2020
Thu, 10 Dec 2020 - Sat, 12 Dec 2020
Fri, 19 Mar 2021 - Sat, 20 Mar 2021